Portrait

Christopher D. Southgate, PhD, Esq.

Attorney for the Life Sciences
Of Counsel at Gearhart Law

chris@cdslaw.org 617-960-9554 Cambridge, MA (Kendall Square)

Services for you:

  • Due Diligence
  • IP Portfolio Strategy
  • Facilitating Matters with Outside Counsel
  • Freedom to Operate
  • Landscape Analysis
  • Patent Application and Prosecution
  • Patent Opposition Proceedings
  • PTAB Appeals
  • Law Firm Experience

  • Lathrop & Gage — Boston, MA
  • Sughrue Mion — Washington, DC
  • Milstein, Zhang & Wu — Brookline, MA
  • Hiscock & Barclay — Boston, MA
  • Palmer & Dodge — Boston, MA
  • Scientific Research Experience

  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Harvard Biolabs
  • Tufts University School of Medicine
  • University of Massachusetts Medical Center
  • Harvard University
  • Qualifications

  • JD, American University, Washington College of Law — Washington, DC, 2013
  • Patent Agent, US Patent and Trademark Office, 2003
  • PhD, Molecular Biology, University of Zurich — Switzerland, 1989
  • Diploma, Swiss Institute for Experimental Cancer (ISREC), University of Lausanne — Switzerland, 1982
  • BS, Biology, University of Lausanne — Switzerland, 1981
  • Inventorship

  • US Patent No. 8,574,567 — “Multipotent stem cells and uses thereof”
  • European Patent No. 2155860 — “Multipotent stem cells and uses thereof”
  • International Background

  • English (native)
  • French (fluent)
  • German (intermediate understanding)
  • Exemplary Clients

  • Vascugen
  • Boston Biomedical
  • Metabolix
  • Exemplary Subjects

  • adult and embryonic stem cell therapies
  • angiogenesis inhibitors
  • antibody glycoforms
  • antibody hinge and Fc variants
  • anti-tumor therapies
  • aptamers
  • biodegradable plastics
  • biofuels
  • cancer stemness inhibitors
  • cancer stem cell biomarkers
  • checkpoint inhibitors
  • combinatorial therapies
  • dietary supplements
  • discovery platform technologies
  • epigenetics (including HDACs)
  • genomics
  • heart valves
  • IgG glycobiology
  • inducible gene expression systems
  • mammalian expression vectors
  • medical diagnostics
  • medical devices
  • microRNAs
  • orthopedics
  • PCR applications
  • recombinant antibody platform technologies
  • recombinant TCR/neoantigen selection
  • RNAi nanoparticle formulations
  • RNAi platform technologies
  • stem cell assays
  • target-specific and multi-specific antibodies
  • TCR co-receptors
  • tissue bioengineering and patterning
  • x-ray crystallography
  • chris@cdslaw.org          617-960-9554